2Sung CO, Oh YL, Song SY. Cervical cytology of atypical squamous cells, cannot exclude high-grade squamous in- tra-epithelial lesion : Significance of age, human papilloma- virus DNA detection and previous abnormal cytology on follow-up outcomes [ J ]. Eur J Obstet Gynecol Reprod Bi- ol,2011,159(1) :155-159.
3Suzanne M, Selvaggi MD. Clinical significance of atypical squamous cells cannot exclude high grade squamous intra- epithelial lesion with histologic correlation-:A 9-year ex- perience [ J ]. Diagnostic Cytopathol, 2013,41 ( 11 ) : 943- 946.
4Ahn S, Lee YY, Sung JY, et al. Body mass index and out- come of asc-h-interpreted cervical smears in postmenopa- usal women [ J ]. Acta Cytologica,2019,56 ( 3 ) :259-265.
5You K, Guo Y, Gen L, et al. The risk of cin ii or greater in a one-year follow-up period in patients with asc-h interpre- ted with cytology [ J ]. Eur J Obstet Gynecol Reprod Biol, 2010,149(2) :215-217.
6Bonvicino A, Huitron S, Fadare O. Papanicolaou test inter- pretations of " atypical squamous ceils, cannot exclude high-grade squamous intraepithelial lesion" [ J ]. Cancer, 2007,111 (6) :477-481.
7Katki HA, Gage JC, Schiffman M, et al. Follow-up testing after colposcopy : five-year risk of CIN 2 + after a colpo- scopie diagnosis of CIN 1 or less [ J ]. J Low Genit Tract Dis ,2013,17 ( 5 ) :69-77.
9Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cer- vical cancer screening tests and cancer precursors [ J ]. Obstet Gynecol,2013,121 (4) :829-846.
10Kietpeerakool C, Cheewakriangkrai C, Suprasert P, et al. Feasibility of the "see and treat" approach in management of women with "atypical squamous cell, cannot exclude high-grade squamous intraepithelial lesion" smears [ J ]. J Obstet Gynaecol Res,2009,35 (3) :507-513.
3Pankin OM, Pisan IP, Ferlay J. Estinates of the worldwide incidence of 25 major cancers. Int Cancer,2007,80(6):827-841.
4Manos MM, Kinney WK, Hurley LB, et al. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal papanicolaou results. JAMA,1999,281(l7):1605-1610.
5Sherman ME, Tabbara SO, Scott DR, et al. "ASCUS, rule out HSIL" : cytologic features, histologic correlates, and human papillomavirus detection. ModPathol,1999,12(4):335-342.
6Solomon 0, Davey 0, Kurman R, et al. The 2001 Bethesda System: terminnology for reporting results of cervical cytology. JAMA,2002, 287(16):2114-2119.
7Lee SJ, Jung KL, Lee JW, et al, Analyses of atypical squamous cells refined by the 200 I Bethesda System: the distribufion and clinical significance of follow-up management. Int J Gynecol Cancer,2006,16(2):664-669.
8Bandyopadhyay S, Austin RM, Dabbs 0, et al. Adjunctive human papillomavirus DNA testing is a useful option in some clinical settings for disease risk assessment and triage of females with ASC-H papanicilaou test results. Arch Pathol Lab Med,2008,132(12):1874-1881.
9Lin CT, Tseng CJ, Lai CH, et al. High-risk HPV DNA detection by Hybrid Capture II. an adjunctive test for mildly abnormal cytologic smears in women > or= 50 years of age. JReport Med,2000,45(4):345-350.
10Shlay JC, Dunn T, Byers T, et al. Prediction of cervical intraepithelial neoplasia grade 223 using risk assessment and human papillomavirus testing in women with atypia on papanicolaou smears. Obstet Gynecol,2000,96(3):41 0416.
